Episode Details

Jorge A. Garcia, MD, FACP, chairperson of the Oncologic Drugs Advisory Committee (ODAC) for the US Food & Drug Administration, shared insight on the recent ODAC meeting where members determined that olaparib plus abiraterone as an upfront treatment for mCRPC should be restricted to patients with BRCA mutations. Dr. Garcia is a medical oncologist at the University Hospitals Seidman Cancer Center and is the center’s George & Edith Richman Distinguished Scientist Chair, as well as Chief of their Solid Tumor Oncology division.